Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...